[{"orgOrder":0,"company":"Invirsa","sponsor":"CincyTech","pharmaFlowCategory":"D","therapeuticArea":"Ophthalmology","country":"","productType":"Small molecule","year":"2023","type":"Series B Financing","leadProduct":"INV-102","moa":"","graph1":"Ophthalmology","graph2":"Phase II","graph3":"Invirsa","amount2":0.01,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0.01,"dosageForm":"Solution\/Drops","sponsorNew":"Invirsa \/ CincyTech","highestDevelopmentStatusID":"8","companyTruncated":"Invirsa \/ CincyTech"}]

Find Clinical Drug Pipeline Developments & Deals by Invirsa

Menu
Xls
Filters Filter
×
FILTER:
filter
Company Name
    filter

    Year

      filter

      DEALS // DEV.

        filter

        Country

          filter
          Sponsor
            filter

            Therapeutic Area

              filter

              Study Phase

                filter

                Deal Type

                  filter

                  Product Type

                    filter

                    Dosage Form

                      filter

                      Lead Product

                        filter

                        Target

                          Loading...

                          Therapeutic Area by Lead Product

                          Study Phase by Lead Product

                          Company by Lead Product

                          Top Deals by Deal Size (USD bn)

                          01

                          2024 ACI Convention
                          Not Confirmed
                          2024 ACI Convention
                          Not Confirmed

                          Details : The net financing will be used in advancing Invirsa's lead product candidate, INV-102, derived from a naturally occurring small molecule, in a series of Phase 2 studies in conditions including acute infectious keratoconjunctivitis, dry eye disease, and F...

                          Brand Name : INV-102

                          Molecule Type : Small molecule

                          Upfront Cash : Undisclosed

                          June 14, 2023

                          Lead Product(s) : Nadolol

                          Therapeutic Area : Ophthalmology

                          Highest Development Status : Phase II

                          Sponsor : CincyTech

                          Deal Size : $7.7 million

                          Deal Type : Series B Financing

                          blank